Moderna says RSV vaccine FDA approval delayed to end of May
Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Friday said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end…
FTC challenges patents held by drugmakers, including for Ozempic
A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. Lee Smith | Reuters The Federal Trade Commission on Tuesday said it…
Pfizer RSV vaccine may protect high-risk adults ages 18-59
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are…
Drugmakers are capping inhaler prices at $35
A woman using an inhaler. BSIP | Universal Images Group | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign…
Pfizer RSV vaccine protects older adults over two seasons
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer’s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an…
GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons
The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | Reuters Over the last 12 months, just 11 stocks…
GSK posts blowout RSV vaccine sales, raises outlook
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit…
Renewed interest in ADCs will continue in 2024
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising…
GSK RSV vaccine shows potential to protect adults 50 to 59
A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial…
Moderna combination Covid, flu vaccine shows positive data
Artur Widak | Nurphoto | Getty Images Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50…